Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.9
3.3
Journals
Brain Sciences
Special Issues
Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening,...
share announcement

Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening, and Regenerative Medicine

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Molecular and Cellular Neuroscience".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 8413

Special Issue Editors

Prof. Dr. Anis Feki

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Hôpital Fribourgeois, Fribourg, Switzerland
Interests: embryonic stem cells; induced pluripotent stem cells; developmental biology; disease modeling; neurodegenerative diseases; neurodevelopmental diseases; 2D and 3D cellular models; organoids; co-culture cellular systems; drug screening; personalized medicine; cellular replacement therapy and regenerative medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Youssef Hibaoui

E-Mail Website
Guest Editor
Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
Interests: embryonic stem cells; induced pluripotent stem cells; developmental biology; disease modeling; neurodegenerative diseases; neurodevelopmental diseases; 2D and 3D cellular models; organoids; co-culture cellular systems; drug screening; personalized medicine; cellular replacement therapy and regenerative medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A major challenge in human neurodevelopmental and neurodegenerative diseases is the understanding of the detailed mechanisms responsible for the clinical features. In fact, the lack of access to the affected tissue has limited the study of the molecular and cell biological aspects of the pathogenesis of such disorders. The discovery that human pluripotent stem cells (PSCs) can be differentiated into virtually any neural cell type and tissue has opened a new field of investigation in human brain developmental biology and disease. Over the last decade, human PSCs (including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)) have emerged as a valuable and powerful material for the study of neurodevelopmental and neurodegenerative diseases. In addition to disease modeling, the main areas of applications for PSCs are drug discovery and regenerative medicine. Indeed, PSCs could also be of great interest in evaluating the efficacy and toxicity of many compounds in drug discovery. Finally, the use of PSC-derived cells in clinical trials has also increased tremendously, as these cells have shown promising therapeutic effects in animal models. 

This Research Topic on “Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening, and Regenerative Medicine” considers original research articles, review articles, commentaries, and perspectives from all areas of brain research, stem cell biology, and organoid research. This includes but is not limited to 2D and 3D cellular models derived from PSCs for disease modeling, developmental biology, drug screening, toxicity testing, tissue engineering approaches, mathematical models, and tissue regeneration. Co-culture cellular systems including neural cells with other cell types will also be considered for publication in this topic.

Prof. Dr. Anis Feki
Dr. Hibaoui Youssef
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • embryonic stem cells
  • induced pluripotent stem cells
  • developmental biology
  • disease modeling
  • neurodegenerative diseases
  • neurodevelopmental diseases
  • neuropsychiatric diseases
  • 2D and 3D cellular models
  • organoids
  • co-culture cellular systems
  • drug screening
  • personalized medicine
  • cellular replacement therapy and regenerative medicine

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 4762 KiB  
Article
Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas
by Rebecca M. Brown, Sameer Farouk Sait, Griffin Dunn, Alanna Sullivan, Benjamin Bruckert and Daochun Sun
Brain Sci. 2022, 12(6), 720; https://doi.org/10.3390/brainsci12060720 - 31 May 2022
Viewed by 1925
Abstract
Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes, affecting up to 1 in 2500 individuals. Up to half of patients with NF1 develop benign nerve sheath tumors called plexiform neurofibromas (PNs), characterized by biallelic NF1 loss. PNs [...] Read more.
Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes, affecting up to 1 in 2500 individuals. Up to half of patients with NF1 develop benign nerve sheath tumors called plexiform neurofibromas (PNs), characterized by biallelic NF1 loss. PNs can grow to immense sizes, cause extensive morbidity, and harbor a 15% lifetime risk of malignant transformation. Increasingly, molecular sequencing and drug screening data from various preclinical murine and human PN cell lines, murine models, and human PN tissues are available to help identify salient treatments for PNs. Despite this, Selumetinib, a MEK inhibitor, is the only currently FDA-approved pharmacotherapy for symptomatic and inoperable PNs in pediatric NF1 patients. The discovery of alternative and additional treatments has been hampered by the rarity of the disease, which makes prioritizing drugs to be tested in future clinical trials immensely important. Here, we propose a gene regulatory network-based integrated analysis to mine high-throughput cell line-based drug data combined with transcriptomes from resected human PN tumors. Conserved network modules were characterized and served as drug fingerprints reflecting the biological connections among drug effects and the inherent properties of PN cell lines and tissue. Drug candidates were ranked, and the therapeutic potential of drug combinations was evaluated via computational predication. Auspicious therapeutic agents and drug combinations were proposed for further investigation in preclinical and clinical trials. Full article
(This article belongs to the Special Issue Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening, and Regenerative Medicine)
►▼ Show Figures

Figure 1

19 pages, 2933 KiB  
Article
The Role of Interstitial Fluid Pressure in Cerebral Porous Biomaterial Integration
by Fabien Bonini, Sébastien Mosser, Flavio Maurizio Mor, Anissa Boutabla, Patrick Burch, Amélie Béduer, Adrien Roux and Thomas Braschler
Brain Sci. 2022, 12(4), 417; https://doi.org/10.3390/brainsci12040417 - 22 Mar 2022
Viewed by 2351
Abstract
Recent advances in biomaterials offer new possibilities for brain tissue reconstruction. Biocompatibility, provision of cell adhesion motives and mechanical properties are among the present main design criteria. We here propose a radically new and potentially major element determining biointegration of porous biomaterials: the [...] Read more.
Recent advances in biomaterials offer new possibilities for brain tissue reconstruction. Biocompatibility, provision of cell adhesion motives and mechanical properties are among the present main design criteria. We here propose a radically new and potentially major element determining biointegration of porous biomaterials: the favorable effect of interstitial fluid pressure (IFP). The force applied by the lymphatic system through the interstitial fluid pressure on biomaterial integration has mostly been neglected so far. We hypothesize it has the potential to force 3D biointegration of porous biomaterials. In this study, we develop a capillary hydrostatic device to apply controlled in vitro interstitial fluid pressure and study its effect during 3D tissue culture. We find that the IFP is a key player in porous biomaterial tissue integration, at physiological IFP levels, surpassing the known effect of cell adhesion motives. Spontaneous electrical activity indicates that the culture conditions are not harmful for the cells. Our work identifies interstitial fluid pressure at physiological negative values as a potential main driver for tissue integration into porous biomaterials. We anticipate that controlling the IFP level could narrow the gap between in vivo and in vitro and therefore decrease the need for animal screening in biomaterial design. Full article
(This article belongs to the Special Issue Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening, and Regenerative Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 4745 KiB  
Review
Advances in Recapitulating Alzheimer’s Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models
by Md Fayad Hasan and Eugenia Trushina
Brain Sci. 2022, 12(5), 552; https://doi.org/10.3390/brainsci12050552 - 26 Apr 2022
Cited by 4 | Viewed by 3175
Abstract
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder and the leading cause of death among older individuals. Available treatment strategies only temporarily mitigate symptoms without modifying disease progression. Recent studies revealed the multifaceted neurobiology of AD and shifted the target of drug development. [...] Read more.
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder and the leading cause of death among older individuals. Available treatment strategies only temporarily mitigate symptoms without modifying disease progression. Recent studies revealed the multifaceted neurobiology of AD and shifted the target of drug development. Established animal models of AD are mostly tailored to yield a subset of disease phenotypes, which do not recapitulate the complexity of sporadic late-onset AD, the most common form of the disease. The use of human induced pluripotent stem cells (HiPSCs) offers unique opportunities to fill these gaps. Emerging technology allows the development of disease models that recapitulate a brain-like microenvironment using patient-derived cells. These models retain the individual’s unraveled genetic background, yielding clinically relevant disease phenotypes and enabling cost-effective, high-throughput studies for drug discovery. Here, we review the development of various HiPSC-based models to study AD mechanisms and their application in drug discovery. Full article
(This article belongs to the Special Issue Pluripotent Stem Cell Applications in Neurological Disease Modeling, Drug Screening, and Regenerative Medicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop